Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
- DOI
- 10.1016/j.jaci.2020.08.037
- Published
- 2020 Dec
- Container
- The Journal of allergy and clinical immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jaci.2020.08.037,
title = {Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.},
author = {Roufosse F and Kahn JE and Rothenberg ME and Wardlaw AJ and Klion AD and Kirby SY and Gilson MJ and Bentley JH and Bradford ES and Yancey SW and Steinfeld J and Gleich GJ and HES Mepolizumab study group},
year = {2020},
journal = {The Journal of allergy and clinical immunology},
doi = {10.1016/j.jaci.2020.08.037},
url = {https://doi.org/10.1016/j.jaci.2020.08.037}
}RIS
TY - JOUR TI - Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. AU - Roufosse F AU - Kahn JE AU - Rothenberg ME AU - Wardlaw AJ AU - Klion AD AU - Kirby SY AU - Gilson MJ AU - Bentley JH AU - Bradford ES AU - Yancey SW AU - Steinfeld J AU - Gleich GJ AU - HES Mepolizumab study group PY - 2020 JO - The Journal of allergy and clinical immunology DO - 10.1016/j.jaci.2020.08.037 UR - https://doi.org/10.1016/j.jaci.2020.08.037 ER -
APA
F, R., JE, K., ME, R., AJ, W., AD, K., SY, K., MJ, G., JH, B., ES, B., SW, Y., J, S., GJ, G., & group, H. M. S. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2020.08.037
Source records
- pubmed · retrieved 2026-09-27T06:53:43.380Z